2023
Enhanced Identification of Hispanic Ethnicity Using Clinical Data
Ochoa-Allemant P, Tate J, Williams E, Gordon K, Marconi V, Bensley K, Rentsch C, Wang K, Taddei T, Justice A, Cohorts F. Enhanced Identification of Hispanic Ethnicity Using Clinical Data. Medical Care 2023, 61: 200-205. PMID: 36893404, PMCID: PMC10114212, DOI: 10.1097/mlr.0000000000001824.Peer-Reviewed Original ResearchConceptsBurden of diseaseHispanic patientsCountry of birthClinical dataHispanic ethnicityNon-Hispanic white patientsSex-adjusted prevalenceChronic liver diseaseHuman immunodeficiency virusDemographic characteristicsElectronic health record dataHealth careHealth record dataPrevalence of conditionsUS health care systemMedicare administrative dataHealth care systemWhite patientsLiver diseaseImmunodeficiency virusSelf-reported ethnicityHigh prevalenceGastric cancerHepatocellular carcinomaVeteran population
2021
The Predictive Role of Model for End‐Stage Liver Disease–Lactate and Lactate Clearance for In‐Hospital Mortality Among a National Cirrhosis Cohort
Mahmud N, Asrani SK, Kaplan DE, Ogola GO, Taddei TH, Kamath PS, Serper M. The Predictive Role of Model for End‐Stage Liver Disease–Lactate and Lactate Clearance for In‐Hospital Mortality Among a National Cirrhosis Cohort. Liver Transplantation 2021, 27: 177-189. PMID: 33025731, PMCID: PMC7880877, DOI: 10.1002/lt.25913.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseHospital mortalityLactate clearanceCirrhosis hospitalizationsMELD-NaLiver diseaseDay 1Predictive roleRetrospective cohort studyIn-Hospital MortalityRisk-stratify patientsVeterans Health AdministrationCirrhosis cohortMELD categoriesGastrointestinal bleedingCohort studyClinical dataLimited cohortStratified analysisLactate levelsHospitalizationHealth AdministrationMELDClinical toolMortality
2020
SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension
Saffo S, Garcia‐Tsao G, Taddei T. SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension. Journal Of Diabetes 2020, 13: 265-269. PMID: 33210815, DOI: 10.1111/1753-0407.13136.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBenzhydryl CompoundsCohort StudiesDiabetes Mellitus, Type 2FemaleGlucosidesGlycated HemoglobinHumansHypertension, PortalLiver CirrhosisMaleMiddle AgedOutcome Assessment, Health CarePolyuriaSodium-Glucose Transporter 2 InhibitorsTertiary Care CentersUrinary Tract InfectionsYoung AdultConceptsSGLT2 inhibitorsPortal hypertensionDiabetes mellitusSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsCenter cohort studyCotransporter 2 inhibitorsCohort of patientsPotential therapeutic targetFavorable pleiotropic effectsCohort studyRenal diseaseClinical trialsClinical dataTherapeutic targetPatientsCirrhosisHypertensionMellitusOngoing evaluationInhibitorsPleiotropic effectsCohortDiseaseTrials